Novo Nordisk’s GLP‑1 RA–A Modern Treatment for Obesity Management–is Linked to Lower Household Spending on Alcohol and Tobacco
Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan. 12, 2026 /PRNewswire/ -- At the international scientific congress ObesityWeek® held late last year in Atlanta, United States, Novo Nordisk presented findings from a real-world analysis of grocery spending data...
Dr.stretch Malaysia partners with NHA athlete Saif Nordin, brings elite mobility and performance to all Malaysians
KUALA LUMPUR, Malaysia, Jan. 12, 2026 /PRNewswire/ -- Dr.stretch Malaysia, the country's leading specialised assisted-stretching brand, is proud to announce a new partnership with national fencer Saif Nordin, one of Malaysia's most promising young athletes who is also a News Hub Asia (NHA) athlete. This collaboration supports Dr.stretch's mission to make professional mobility, recovery, and performance care accessible to...
WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data, with revenue from Continuing Operations growing by approximately 21.4% year-over-year. Important notices of the announcement are as follows: WuXi...
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation...
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active rheumatoid...
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an...
Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies' commitment to advancing oncology research by...
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in...
Yuwell Medical Makes Its Debut at CES 2026: AI Expands the Boundaries of Health Management
LAS VEGAS, Jan. 9, 2026 /PRNewswire/ -- From January 6 to 9, CES 2026, held in Las Vegas—brought together 4,112 leading enterprises from around the world. As a leading Chinese medical device company, Yuwell Medical made its debut at CES. Yuwell Medical Makes Its Debut at CES 2026: AI Expands the Boundaries of Health Management At the exhibition,...
Professor Wong Tin Chee Honored as GQ Hong Kong’s Local Hero 2025 Giving Back to Society with TCM Wisdom Launches “The Pain Management CEO” Video Series Sharing the Path...
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Wong Tin-Chee, Founder of Herbalgy Pharmaceutical Ltd. and Professor of Traditional Chinese Medicine, has been honored as one of the Local Heroes in GQ Hong Kong's Men of the Year 2025, in recognition of his long-standing commitment to advancing pain management through Traditional Chinese...
